Analyst
BTIG
Equibles does not estimate personal net worth.
Sam Eiber is recorded as Analyst at BTIG. Sam Eiber has spoken on 6 earnings calls across 4 companies, most recently for Evolus, Inc. on August 5, 2026. Those appearances were for Evolus, Inc. (EOLS), InMode Ltd. (INMD), Apyx Medical Corp (APYX) and Dexcom Inc (DXCM). The companies whose calls Sam Eiber spoke on are classified in the Healthcare sector.
“Just to start out, it's a little bit of a higher-level question, but you're ramping on Evelisse in the U.S., expanding OUS with the new CIMITES agreement. You signed this Profilo agreement.”
“Hopping between a few calls this morning, so apologies if this question already got asked, but maybe just following back up on capital allocation and maybe diving a bit deeper in terms of appetite for M&A. I know it's something that, you know, you guys have always been considering, but, you know, haven't seen, you…”
“Maybe I can just start on Esteem and with the launch coming up here in May. I guess, should we expect any initial stocking order similar to what we saw with Evelisse in the U.S. in Q2 of last year?”
“Charlie, sitting here, I guess, six months into the AYON launch, what's been going well? What's going better than expectations? What are some things that maybe you have to fine-tune?”
“Maybe just following up on the last question, I guess how should we think about the low growth perhaps accelerating in 2027 with the Sculp launch? I guess are accounts waiting for the product, or does it necessarily just change the conversation you're able to have with providers here?”
BTIG
Analyst
Source not stated
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
INMD
Medical Devices · Healthcare
APYX
Medical Devices · Healthcare
DXCM
Medical Devices · Healthcare
